News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Infinity Pharmaceuticals Inc. (INFI) Reports Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 Across a Broad Range of Blood Cancers at the 12th International Conference on Malignant Lymphoma


6/24/2013 8:00:16 AM

Sign up for the free GenePool newsletter today!

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers. Data from the study showed that IPI-145 was well tolerated and clinically active across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Hodgkin lymphoma (HL) and T-cell lymphomas.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES